Correction to: Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study

Abstract Background: Complementary experiments on nanomedicines as proper candidates for the control and treatment of cancer are widely being conducted nowadays. In the previous study, the effect of BCc1 nanomedicine, which is synthetized based on nanochelating technology, on overall survival (OS) and quality of life of gastric cancer patients was evaluated after 18 months of consumption. The OS of the same patients is reported in this study after 40 months. Methods: A double-blind, randomized, placebo-controlled, parallel, multicenter design was used in this study. 123 metastatic and non-metastatic gastric cancer patients of both genders (between 25 and 85 years old) participated in this experiment to evaluate their OS after consuming BCc1 for 40 months and to identify the adverse events of this nanomedicine. Results: The median OS of metastatic patients was 257 days in the BCc1 group [95% confidence interval (CI): 144. 142-369.858], while it was 161 days in the placebo [95% CI: 118.462-203.538]; hazard ratio (HR): 0.802 [95% CI: 0.483-1.333] (P-Value = 0.395). Similarly, the median OS of non-metastatic patients was 718 days in the BCc1 group [95% CI; 577.706-860.213], while it was 520 days in the placebo [95% CI: 460.280- 580.690]; HR: 0.807 [95% CI: 0.343,1.902] (P-Value = 0.624). There was no evidence of adverse events after 40 months.Conclusion: The OS improvement of metastatic and non-metastatic gastric cancer patients in the previous (18 months of follow-up) and current (40 months of follow-up) studies showed that BCc1 can be used along with base treatments to improve cancer patients’ OS. Trial registration: IRCTID, IRCT2017101935423N1.Registered on 19 October 2017, http://www.irct.ir/ IRCT2017101935423N1.

Download Full-text

Early presence of antiangiogenesis-related adverse events as a potential biomarker of antitumor efficacy in patients with metastatic gastric cancer treated with apatinib.

Journal of Clinical Oncology ◽

10.1200/jco.2017.35.15_suppl.4052 ◽

2017 ◽

Vol 35 (15_suppl) ◽

pp. 4052-4052

Author(s):

Xinyang Liu ◽

Shukui Qin ◽

Zhichao Wang ◽

Jianming Xu ◽

Jianping Xiong ◽

...

Keyword(s):

Gastric Cancer ◽

Adverse Events ◽

Clinical Outcomes ◽

Progression Free Survival ◽

Metastatic Gastric Cancer ◽

Antitumor Efficacy ◽

Sensitivity Analyses ◽

Risk Scores ◽

Potential Biomarker ◽

Landmark Analyses

4052 Background: Reliable biomarkers of apatinib response in gastric cancer (GC) are lacking. We investigated the association between early presence of common adverse events (AEs) and clinical outcomes in metastatic GC patients. Methods: We conducted a retrospective cohort study using data on 269 apatinib-treated GC patients in two clinical trials. AEs were assessed at baseline until 28 days after the last dose of apatinib. Clinical outcomes were compared between patients with and without hypertension (HTN), proteinuria or hand and foot syndrome (HFS) in the first 4 weeks using Kaplan–Meier methods, Cox proportional hazard regression and logistic regression models. Landmark analyses were performed as sensitivity analyses. Predictive model and risk scores were analyzed to predict overall survival (OS). Results: Presence of AEs in the first 4 weeks was associated with prolonged median OS (169 vs. 103 days, log-rank p=0.0039; adjusted hazard ratio [HR] 0.64, 95% confidence interval [CI] 0.64-0.84, p=0.001), prolonged median progression-free survival (PFS, 87 vs. 62 days, log-rank p=0.0309; adjusted HR 0.69, 95%CI 0.53-0.91, p=0.007), and increased disease control rate (54.67% vs. 32.77%; adjusted odds ratio 2.67, p<0.001). Results remained significant in landmark analyses. An AE-based prediction model and subsequently derived scoring system showed high calibration and discrimination in predicting OS. Conclusions: Presence of HTN, proteinuria or HFS during the first cycle of apatinib treatment was a viable biomarker of antitumor efficacy in metastatic GC patients. [Table: see text]

Download Full-text

Severe Loss of Visceral Fat and Skeletal Muscle After Chemotherapy Predict Poor Prognosis in Metastatic Gastric Cancer Patients Without Gastrectomy

SSRN Electronic Journal ◽

10.2139/ssrn.3391371 ◽

2019 ◽

Author(s):

Wanjing Feng ◽

Mingzhu Huang ◽

Xiaoying Zhao ◽

Siyuan Chen ◽

Chenchen Wang ◽

...

Keyword(s):

Gastric Cancer ◽

Skeletal Muscle ◽

Cancer Patients ◽

Visceral Fat ◽

Poor Prognosis ◽

Metastatic Gastric Cancer ◽

Severe Loss ◽

Gastric Cancer Patients

Download Full-text

P21-Activated Kinase 4 Overexpression in Metastatic Gastric Cancer Patients

Translational Oncology ◽

10.1593/tlo.11145 ◽

2011 ◽

Vol 4 (6) ◽

pp. 345-349 ◽

Cited By ~ 38

Author(s):

Hee Kyung Ahn ◽

Jiryeon Jang ◽

Jeeyun Lee ◽

Hoon Park Se ◽

Joon Oh Park ◽

...

Keyword(s):

Gastric Cancer ◽

Cancer Patients ◽

Metastatic Gastric Cancer ◽

P21 Activated Kinase ◽

Gastric Cancer Patients

Download Full-text

Prediagnosis lifestyle exposures and survival of gastric cancer patients: a cohort study from Portugal

British Journal of Cancer ◽

10.1038/bjc.2012.258 ◽

2012 ◽

Vol 107 (3) ◽

pp. 537-543 ◽

Cited By ~ 10

Author(s):

I Ferronha ◽

C Castro ◽

H Carreira ◽

M J Bento ◽

I Carvalho ◽

...

Keyword(s):

Gastric Cancer ◽

Cohort Study ◽

Cancer Patients ◽

Gastric Cancer Patients

Download Full-text

Simple combinations of 5-FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S-1

International Journal of Cancer ◽

10.1002/ijc.22080 ◽

2006 ◽

Vol 119 (8) ◽

pp. 1927-1933 ◽

Cited By ~ 41

Author(s):

Wataru Ichikawa ◽

Takehiro Takahashi ◽

Kenichi Suto ◽

Yoshinori Shirota ◽

Zenro Nihei ◽

...

Keyword(s):

Gastric Cancer ◽

Cancer Patients ◽

Metastatic Gastric Cancer ◽

Gastric Cancer Patients

Download Full-text

The role of nutritional assessment for predicting Radiotherapy-induced adverse events in patients with gastric cancer

British Journal of Radiology ◽

10.1259/bjr.20201004 ◽

2021 ◽

Author(s):

Wenjie Sun ◽

Guichao Li ◽

Jing Zhang ◽

Ji Zhu ◽

Zhen Zhang

Keyword(s):

Gastric Cancer ◽

Body Weight ◽

Adverse Events ◽

Cancer Patients ◽

Body Weight Loss ◽

Nutritional Factors ◽

Nrs 2002 ◽

Grade 3 ◽

Gastric Cancer Patients

Objectives: The aim of this study was to investigate the role of nutritional factors in predicting radiotherapy-associated toxicities for gastric cancer patients. Methods: A total of 285 gastric cancer patients who underwent radiotherapy in our hospital between 2010 and 2017 were included in this retrospective study. Nutritional status assessment included body weight loss (BWL), body mass index (BMI), serum albumin, nutrition risk screening 2002(NRS-2002), patient-generated subjective global assessment(PG-SGA) and nutritional risk index (NRI). Results: Of all patients, 19.6% were underweight (BMI <18.5 kg/m2), 25.6% were hypoalbuminemia (<35 g l−1) and 48.8% lost ≥10% of body weight in the 6 month interval before radiotherapy(BWL). Meanwhile, 73.3%, 78.6 and 47.2% of the patients were diagnosed as malnutrition based on NRS-2002, PG-SGA and NRI, respectively. Hematological adverse events were present in 91.2% (≥Grade 1) and 20.4% (≥Grade 3) of the patients. Non-hematological adverse events occurred in 89.8% (≥Grade1) and 14.4% (≥Grade 3) of the patients. Multivariate analyses indicated that only hypoalbuminemia(<35 g l−1) was independent predictor for Grade 3/4 hematological and non-hematological adverse events. Meanwhile, higher BWL(≥10%) was also independent predictor for Grade 3/4 non-hematological adverse events. NRS-2002, PG-SGA and NRI score were not associated with treatment-induced adverse events. Conclusions: Body weight loss and serum albumin are useful factors for predicting severe adverse events in gastric cancer patients who undergo radiotherapy. Advances in knowledge: The use of nutritional factors in predicting severe adverse events enables implementation of individualized treatment strategies for early and intensive nutritional interventions in high-risk patients.

Download Full-text